UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
| | | |
| (Commission File Number) | (IRS Employer Identification No.) | |
| | | |
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| | |
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On June 28, 2022, the United States Patent and Trademark Office (the “USPTO”) issued U.S. Patent No. 11371037 (the “037 Patent”) and made publicly available provisional patent application (U.S. Application No. 17/374.357) (the “Provisional Patent Applications”) to which the 371 Patent claims priority.
The 037 Patent and the Provisional Patent Application described an invention that is directed to a method of preparing zinc-charged pancreatic enzymes, which is further directed to a method of treating cancer and inflammation using the zinc-charged pancreatic enzymes. Charging the pancreatic enzymes with zinc ions activate the pancreatic enzyme’s anticancer and anti-inflammation properties and make the enzymes capable of being administered orally. It is observed that the zinc-charged pancreatic enzymes are able to induce apoptosia in various cancer cells without affecting the normal cells. The zinc-charged pancreatic enzymes have also been observed inducing apoptosis in trophoblasts and reducing inflammation in general.
Our study has revealed that amylase-Zn possesses multiple anticancer mechanisms. First, in additional to the induction of apoptosis, amylase-Zn reduced the expression of PD-L1 in cancer cell lines by 90%, suggesting that amylase-Zn may be used as an immunotherapy agent for cancer treatment. Secondly, amylase-Zn reduced the expression of c-Myc by 45%, which may inhibit tumor growth. Third, amylase-Zn inhibited the secretion of IL-6, IL-8 and TNF-alpha, suggesting that amylase-Zn may inhibit cancer metastasis.
In vitro, cell lines study showed that amylase-Zn has strong apoptosis-inducing activity on various pancreatic cancer cell lines such as: BxPC-3, AsPC-1, HPAF-II, and Capan-2. Tissue distribution study further showed that after amylase-Zn was administrated to mice, a high concentration of amylase-Zn was detected in pancreas homogenate. Hence, amylase-Zn may be developed as an anti-pancreatic cancer drug, which will be the focus of the research for this IND application. The efficacy of amylase on pancreatic cancer, toxicology study, and pharmacokinetics study will be all performed as part of this exploration.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
AMERICA GREAT HEALTH
Date: July 22, 2022
By: /s/ Mike Q. Wang
Name: Mike Q. Wang
Title: CEO